Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
March 15, 2021 6:21 AM EDTH.C. Wainwright analyst Ed Arce upgraded Iterum Therapeutics (NASDAQ: ITRM) from Neutral to Buy with a price target of $2.50.
The analyst comments "Recent financings provide substantial runway, allowing investor focus to turn to potential FDA approval and launch. We downgraded ITRM last June on an unclear regulatory path forward for sulopenem (it had missed the primary endpoint on two of three Phase 3 trials) and a short cash runway without an ability to commercialize the drug (or a partner), even... More
Iterum Therapeutics Plc (ITRM) Tops Q4 EPS by 8c
March 12, 2021 7:09 AM ESTIterum Therapeutics Plc (NASDAQ: ITRM) reported Q4 EPS of ($0.11), $0.08 better than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.
... More